- Conditions
- Rupture of Anterior Cruciate Ligament
- Interventions
- Somatropin, Placebo
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Osteoarthritis, Knee
- Interventions
- UBX0101, Placebo
- Drug · Other
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- El Cajon, California • La Mesa, California • Miami, Florida + 4 more
- Conditions
- Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Interventions
- anti-CD14, Placebo, remdesivir
- Biological · Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Seattle, Washington
- Conditions
- Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
- Interventions
- ozarelix, Placebo
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Cocaine Use Disorder
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- Christopher D. Verrico
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Covid19
- Interventions
- COVI-AMG, Placebo
- Biological · Drug
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Brandon, Florida
- Conditions
- Healthy, Safety Evaluation of Escalating Doses, Tolerability
- Interventions
- Nezavist SDD, Placebo
- Drug
- Lead sponsor
- Lohocla Research Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Interventions
- Insulin, Placebo (Sterile diluent)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
- Interventions
- AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, Placebo, AAV2-hAQP1 Concentration 3, AAV2-hAQP1 Concentration 4
- Genetic · Other
- Lead sponsor
- MeiraGTx, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • Miami, Florida + 14 more
- Conditions
- Neuropathic Pain
- Interventions
- onabotulinum toxin A
- Drug
- Lead sponsor
- Isabel Moreno Hay
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
- Biological · Other · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
- Conditions
- Diabetes
- Interventions
- BD Scarlett Infusion set, Medtronic QuickSet Infusion Set
- Device
- Lead sponsor
- Becton, Dickinson and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Von Willebrand Disease
- Interventions
- Vonicog alfa, Antihemophilic Factor (Recombinant)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 16
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more
- Conditions
- Yellow Fever Immunization
- Interventions
- Yellow fever vaccine (live), YF vaccine (live)
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 640 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Decatur, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more
- Conditions
- Atrial Fibrillation With Rapid Ventricular Response, Hypotension Drug-Induced
- Interventions
- Calcium pre-treatment, Placebo
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Oak Lawn, Illinois
- Conditions
- COVID-19
- Interventions
- STI-9199, Placebo
- Drug
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Dengue
- Interventions
- TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3, TetraVax-DV Vaccine-Admixture 4, Placebo, TetraVax-DV Vaccine-Admixture 5
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Burlington, Vermont
- Conditions
- Influenza
- Interventions
- Placebo, Trivalent Inactivated Influenza
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Interventions
- tanespimycin, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Idiopathic Intracranial Hypertension
- Interventions
- Presendin, Placebo
- Drug
- Lead sponsor
- Invex Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more
- Conditions
- Avian Influenza, Influenza Immunisation
- Interventions
- A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent
- Biological · Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 14
- States / cities
- Bradenton, Florida • St. Petersburg, Florida • Mason City, Iowa + 11 more
- Conditions
- Staphylococcal Vaccine
- Interventions
- Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 3,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 234
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide once weekly, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska